TG THERAPEUTICS INC. - COMMON STOCK

28.77

08-January-25 16:45:00

15 minutes delayed

Stocks

+0.77

+2.75%

Today's range

27.55 - 28.88

ISIN

N/A

Source

NASDAQ

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results

02 Mar 2021 07:00:01 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update

26 Feb 2021 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology

23 Feb 2021 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

05 Feb 2021 13:54:45 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference

15 Jan 2021 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

08 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

<<
<
4
5
6
7
8
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.